Experienced in Low Sodium Level

Anastasios Stathis

Bellinzona, TI, CH 
Experienced in Low Sodium Level
Bellinzona, TI, CH 
OverviewLocationsClinical Research

Overview

Anastasios Stathis practices in Bellinzona, Switzerland. Mr. Stathis is rated as an Experienced expert by MediFind in the treatment of Low Sodium Level. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Diffuse Large B-Cell Lymphoma (DLBCL), and Tissue Biopsy.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Low Sodium Level.

Gender
Male

Locations

Bellinzona, TI 6500, Switzerland
Other Locations
Lugano, TI, Switzerland
Bellinzoona, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)
Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Drug
Study Drugs: Tafasitamab, Acalabrutinib
Study Phase: Phase 2
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
Enrollment Status: Terminated
Publish Date: December 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Enrollment Status: Terminated
Publish Date: September 28, 2022
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 1
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Enrollment Status: Terminated
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Venetoclax
Study Phase: Phase 1
Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Completed
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR
DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR
Enrollment Status: Completed
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

131 Total Publications

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stathis's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile